Navigation Links
Nancy Brinker to receive 2009 Porter Prize
Date:3/9/2009

PITTSBURGH, March 9 Nancy Brinker, famed breast cancer activist and founder of Susan G. Komen for the Cure, will be the 2009 recipient of the University of Pittsburgh Graduate School of Public Health's (GSPH) Porter Prize in recognition of her outstanding achievements promoting health and preventing disease. Ms. Brinker ignited the global breast cancer movement nearly 30 years ago when she promised her dying sister, Susan G. Komen, that she would put an end to the pain, fear and hopelessness associated with the disease. Ms. Komen died of breast cancer at the age of 36.

Ms. Brinker will be honored at 5:30 p.m., Thursday, March 12, at an invitation-only reception at the Sheraton Station Square. Members of the media are welcome to attend.

Among the audience will be breast cancer survivors and researchers who are part of the Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project (NSABP) the world's most influential clinical cancer program. Since 1974, GSPH has directed the NSABP's Biostatistical Center, serving as the foundation for the project's numerous studies that have led to groundbreaking improvements in breast cancer care.

"We are delighted to honor Ms. Brinker with the 2009 Porter Prize," said Donald S. Burke, M.D., GSPH dean and UPMC-Jonas Salk Chair of Global Health. "Her determination and vision to create a world without breast cancer mirrors our own efforts to save lives and energize science to find cures for disease."

Since Ms. Brinker founded Susan G. Komen for the Cure in 1982, it has grown into a global organization of volunteers who raise money and awareness through local affiliates and sponsor Komen Race for the Cure events across the country. Since the first race was held in Dallas in 1983, the Komen organization has grown to sponsor more than 100 races annually across the globe, drawing more than one million participants. Locally, the Komen Pittsburgh Race for the Cure takes place on Mother's Day every year to raise community awareness and funding for breast cancer education and scientific research, and to honor breast cancer survivors and those who have died of the disease.

At the time the organization was founded, the words "breast cancer" were rarely uttered in public. Few treatment options existed and funding for breast cancer research was scarce. Within a few years, Ms. Brinker succeeded in overcoming the silence surrounding the disease, changing the way it is talked about and treated. Today, the Komen organization is recognized as the nation's leading catalyst in the fight against breast cancer, with more than 100,000 volunteers working in a network of 125 U.S. and international affiliates.

In addition to her work with the Komen organization, Ms. Brinker served as U.S. Ambassador to the Republic of Hungary during the Bush administration where she advanced a broad range of U.S. security and economic interests. She also served as the administration's Chief of Protocol of the United States.


'/>"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Celebrity Chef Cat Cora Announces First Pregnancy
2. National Alliance for Hispanic Health Congratulates Governor Kathleen Sebelius and Nancy-Ann DeParle
3. AHIP Statement on Governor Sebelius and Nancy-Ann DeParle
4. No differences in survival or neonatal outcomes in pregnancy-associated colorectal cancer
5. Diabetes Linked to Depression During and After Pregnancy
6. Parents avoid pregnancy rather than face testing choices
7. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
8. Nordic Naturals Becomes the Official Omega-3 of the American Pregnancy Association
9. Pregnancy has no impact on breast cancer, but can delay diagnosis and treatment
10. Study finds pregnancy has no impact on breast cancer survival, delays treatment, diagnosis
11. Zinc May Counter Effects of Alcohol in Early Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus ... from 9 am to 3 pm to present to graduate students exciting new and ... an original curriculum project led by The Health Improvement Service of the Western Health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, ... families and business owners in North Central West Virginia, is embarking on a ... differently abled residents in the region. , The Stepping Stones organization offers a ...
(Date:6/22/2017)... Indianapolis, IN (PRWEB) , ... June 22, 2017 ... ... employee benefits advisory organization, is pleased to welcome Whipple & Company as its ... on the clear purpose of balancing their clients’ risk while tailoring optimized benefit ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... awards for environmental excellence. Maryland Recycling Network has awarded the Baltimore VA Medical ... Outstanding Small Government Program Award for its efforts to promote waste reduction and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... that Claritas Capital, a Nashville-based private equity firm, has invested $3.35 million in ... for some time, and Claritas Capital offers the smart money, speed to market ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: